Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses

Blood (2024) 144 (15): 1595–1610.

https://doi.org/10.1182/blood.2023022884

Published: 2024

Includes: Supplemental data

Journal Articles

Lysosomal Membrane Permeabilization Sensitizes Ctss-Hyperactive Tumors to BCL2-Targeting Therapies

Blood (2023) 142 (Supplement 1): 4358.

https://doi.org/10.1182/blood-2023-174384

Published: 2023

Journal Articles

An Evidence Based Reporting System for Molecular Tumorboards Identifies Novel Therapeutics for T-Cell Lymphomas

Nicole Schmidt, Kevin Kornrumpf, Lena Ries, Bjoern Chapuy, Charlotte Höltermann, Tim Beißbarth, Jürgen Dönitz, Raphael Koch

Blood (2022) 140 (Supplement 1): 11896–11897.

https://doi.org/10.1182/blood-2022-167435

Published: 2022

Journal Articles

Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent Kinase-9 (CDK9) Inhibitor AZD4573 in Relapsed/Refractory Hematological Malignancies: A Phase 1 First-in-Human Study

Tim H. Brummendorf, Patrick Medd, Raphael Koch, Stephan Stilgenbauer, Shringi Sharma, Yun He, Stefanie Meyer, Margaret C. Wey, Jamal Saeh, Richard F. Olsson, Arnon P. Kater

Blood (2022) 140 (Supplement 1): 3126–3127.

https://doi.org/10.1182/blood-2022-167203

Published: 2022

Journal Articles

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

Blood (2022) 139 (13): 2024–2037.

https://doi.org/10.1182/blood.2021014701

Published: 2022

Includes: Supplemental data

Journal Articles

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

Steven M. Horwitz, Kerry J. Savage, Tim Illidge, Swaminathan P Iyer, Ranjana Advani, Andrei R Shustov, Nancy L. Bartlett, Barbara Pro, Eric D Jacobsen, Raphael Koch, Domingo Domenech Eva, Michelle A. Fanale, Keenan Fenton, Frank Campana, Cassie Dong, Lorenz Truemper

Blood (2021) 138 (Supplement 1): 135.

https://doi.org/10.1182/blood-2021-145124

Published: 2021

Journal Articles

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Yonghan He, MD, Raphael Koch, Vivekananda Budamagunta, Dongwen Lv, Sajid Khan, Xuan Zhang, Janet S Wiegand, Guangrong Zheng, David M. Weinstock, MD, Daohong Zhou

Blood (2019) 134 (Supplement_1): 303.

https://doi.org/10.1182/blood-2019-125820

Published: 2019

Journal Articles

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

Raphael Koch, Amanda L. Christie, Jennifer L. Crombie, Adam C. Palmer, Deborah Plana, Kay Shigemori, Sara N. Morrow, Alexandria Van Scoyk, Wenchao Wu, Elizabeth A. Brem, J. Paul Secrist, Lisa Drew, Alwin G. Schuller, Justin Cidado, Anthony Letai, David M. Weinstock

Blood (2019) 133 (6): 566–575.

https://doi.org/10.1182/blood-2018-07-865527

Published: 2019

Includes: Supplemental data

Journal Articles

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Blood (2018) 131 (8): 888–898.

https://doi.org/10.1182/blood-2017-08-802470

Published: 2018

Includes: Supplemental data

Journal Articles

In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924

Raphael Koch, MD, Amanda L Christie, BS, Noriaki Yoshida, MD PhD, Samuel Y. Ng, MDPhD, Kay Shigemori, Sara N Morrow, Alexandria Van Scoyk, Steven M. Horwitz, MD, Eric Jacobsen, MD, Solimar Santiago, Jian-Guo Ren, Vincent Guerlavais, PhD, D. Allan Annis, Manuel A. Aivado, MD PhD, David M. Weinstock, MD

Blood (2017) 130 (Supplement 1): 571.

https://doi.org/10.1182/blood.V130.Suppl_1.571.571

Published: 2017

Journal Articles

In Vitro , In Vivo , and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma

Alison J. Moskowitz, MD, Raphael Koch, MD, Neha Mehta-Shah, MD, Patricia Myskowski, MD, Meenal Kheterpal, MD, Ahmet Dogan, MD PhD, Theresa Davey, MPAS, Natasha Galasso, BA, Marzouk Evan, BA, Monica Shah, BA, Nivetha Ganesan, BS, Lakeisha Lubin, BS, Youn H. Kim, MD, Michael Khodadoust, MD PhD, Timothy Almazan, MD, Julia Dai, MD, Eric D. Jacobsen, MD, David M. Weinstock, MD, Steven M. Horwitz, MD

Blood (2017) 130 (Supplement 1): 819.

https://doi.org/10.1182/blood.V130.Suppl_1.819.819

Published: 2017

Journal Articles

T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development

Blood (2016) 128 (22): 3015.

https://doi.org/10.1182/blood.V128.22.3015.3015

Published: 2016

Journal Articles

A Functional Characterization of BCL2-Family Members Identifies BH3 Mimetics As Potential Therapeutics in T-Cell Lymphomas

Raphael Koch, MD, Elizabeth Brem, MD, Rachael Clark, MD PhD, Thomas S. Kupper, MD, Anthony Letai, MD PhD, David M. Weinstock, MD

Blood (2016) 128 (22): 292.

https://doi.org/10.1182/blood.V128.22.292.292

Published: 2016

Journal Articles

Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma

Mark A. Murakami, MD MA, Alexandra N. Christodoulou, M.S., Amanda L Christie, B.S., Tiffany DeSouza, B.S., Abner Louissaint, Jr., MD PhD, Una Vojinovic, B.S., Raphael Koch, MD, Loretta S. Li, MD, Scott P. Kallgren, PhD, Prakash Rao, PhD, Johannes Köster, PhD, Raga Vadhi, M.S., Eilene Duberow, B.S., Elizabeth A. Morgan, MD, Hongjun Wang, Samia S. Ahmed, Katharine L. Majewski, Marina Konopleva, MD PhD, Jerome Tamburini, MD, PhD, Alejandro Gutierrez, MD, Michelle Kelliher, PhD, Julia Etchin, PhD, Irmela Jeremias, MD, Andrew P. Weng, MD PhD, Andrew L Kung, MD PhD, Andrew A Lane, MD PhD, Francine Garnache-Ottou, PhD, Shai Izraeli, MD Prof, Eric Jacobsen, MD, Ilene Galinsky, ANP, Richard M. Stone, MD, Marian H. Harris, MD PhD, David M. Dorfman, MD PhD, Jon C Aster, MDPhD, Henry Long, PhD, Lewis B. Silverman, MD, David M Weinstock, MD

Blood (2015) 126 (23): 3252.

https://doi.org/10.1182/blood.V126.23.3252.3252

Published: 2015

Journal Articles

SFRP4-Mediated Inhibition of Canonical Wnt-Signaling in DLBCL

Raphael Koch, MD, Bjoern Chapuy, MD PhD

Blood (2015) 126 (23): 3999.

https://doi.org/10.1182/blood.V126.23.3999.3999

Published: 2015

Journal Articles

B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development

Blood (2015) 126 (23): 4001.

https://doi.org/10.1182/blood.V126.23.4001.4001

Published: 2015

Journal Articles

Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma

Raphael Koch, Martin Demant, Thiha Aung, Nina Diering, Anna Cicholas, Bjoern Chapuy, Dirk Wenzel, Marlen Lahmann, Annemarie Güntsch, Christina Kiecke, Sabrina Becker, Timo Hupfeld, Vivek Venkataramani, Marita Ziepert, Lennart Opitz, Wolfram Klapper, Lorenz Trümper, Gerald G. Wulf

Blood (2014) 123 (14): 2189–2198.

https://doi.org/10.1182/blood-2013-08-523886

Published: 2014

Includes: Supplemental data

Journal Articles

Exosome Mediated Wnt-Signaling Augments Side Population In Aggressive Lymphoma

Raphael Koch, Martin Demant, Thiha Aung, Annemarie Guentsch, Nina Diering, Bjoern Chapuy, MD, PhD, Lorenz Truemper, Gerald Wulf, MD

Blood (2013) 122 (21): 3010.

https://doi.org/10.1182/blood.V122.21.3010.3010

Published: 2013

NARROW

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses

Lysosomal Membrane Permeabilization Sensitizes Ctss-Hyperactive Tumors to BCL2-Targeting Therapies

An Evidence Based Reporting System for Molecular Tumorboards Identifies Novel Therapeutics for T-Cell Lymphomas

Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent Kinase-9 (CDK9) Inhibitor AZD4573 in Relapsed/Refractory Hematological Malignancies: A Phase 1 First-in-Human Study

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924

In Vitro , In Vivo , and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma

T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development

A Functional Characterization of BCL2-Family Members Identifies BH3 Mimetics As Potential Therapeutics in T-Cell Lymphomas

Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma

SFRP4-Mediated Inhibition of Canonical Wnt-Signaling in DLBCL

B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development

Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma

Exosome Mediated Wnt-Signaling Augments Side Population In Aggressive Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only